BAUSCH Company Profile

✉ Email this page to a colleague

What is the competitive landscape for BAUSCH, and when can generic versions of BAUSCH drugs launch?

BAUSCH has one hundred and seventy-seven approved drugs.

There are one hundred and twenty-eight US patents protecting BAUSCH drugs.

There are seven hundred and seventy-eight patent family members on BAUSCH drugs in fifty-three countries and two hundred and fourteen supplementary protection certificates in sixteen countries.

Summary for BAUSCH

International Patents:	778
US Patents:	128
Tradenames:	156
Ingredients:	122
NDAs:	177
Patent Litigation for BAUSCH:	See patent lawsuits for BAUSCH

Drugs and US Patents for BAUSCH

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ARAZLO	tazarotene	LOTION;TOPICAL	211882-001	Dec 18, 2019		RX	Yes	Yes	12,128,137	⤷ Subscribe	Y			⤷ Subscribe
Bausch	CABTREO	adapalene; benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	216632-001	Oct 20, 2023		RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Bausch And Lomb Inc	XIIDRA	lifitegrast	SOLUTION/DROPS;OPHTHALMIC	208073-001	Jul 11, 2016		RX	Yes	Yes	9,216,174	⤷ Subscribe	Y			⤷ Subscribe
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-002	Apr 23, 2008		RX	Yes	No	7,645,802	⤷ Subscribe	Y			⤷ Subscribe
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	AB	RX	Yes	Yes	10,085,958	⤷ Subscribe	Y			⤷ Subscribe
Bausch And Lomb	LOTEMAX	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	020583-001	Mar 9, 1998	AB	RX	Yes	Yes		⤷ Subscribe				⤷ Subscribe
Bausch	JUBLIA	efinaconazole	SOLUTION;TOPICAL	203567-001	Jun 6, 2014	AB	RX	Yes	Yes	9,566,272	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for BAUSCH

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	SOLODYN	minocycline hydrochloride	TABLET, EXTENDED RELEASE;ORAL	050808-008	Aug 27, 2010	5,908,838	⤷ Subscribe
Bausch	ZELAPAR	selegiline hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021479-001	Jun 14, 2006	6,423,342	⤷ Subscribe
Bausch	ZOVIRAX	acyclovir	CREAM;TOPICAL	021478-001	Dec 30, 2002	4,963,555	⤷ Subscribe
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	8,754,131	⤷ Subscribe
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-003	Feb 6, 2003	5,529,791	⤷ Subscribe
Bausch	WELLBUTRIN XL	bupropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021515-002	Aug 28, 2003	6,096,341	⤷ Subscribe
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-005	Feb 6, 2003	6,923,984	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for BAUSCH drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Vaginal Gel	0.75%	➤ Subscribe	2004-09-02
➤ Subscribe	Cream	5%	➤ Subscribe	2006-10-17
➤ Subscribe	Topical Solution	10%	➤ Subscribe	2018-06-06
➤ Subscribe	Cream	0.10%	➤ Subscribe	2008-01-31
➤ Subscribe	Extended-release Tablets	348 mg	➤ Subscribe	2009-09-24
➤ Subscribe	Cream	2.5%	➤ Subscribe	2014-06-17
➤ Subscribe	Extended-release Tablets	120 mg, 180 mg, 240 mg, 300 mg and 360 mg	➤ Subscribe	2005-08-30
➤ Subscribe	Rectal Gel	2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL	➤ Subscribe	2004-03-23
➤ Subscribe	Extended-release Tablets	65 mg and 115 mg	➤ Subscribe	2009-11-19
➤ Subscribe	Rectal Gel	5 mg/mL, 2mL pre-filled syringe	➤ Subscribe	2008-12-23
➤ Subscribe	Extended-release Tablet	105 rng	➤ Subscribe	2010-12-28
➤ Subscribe	Gel	1.2%/3.75%	➤ Subscribe	2015-09-30
➤ Subscribe	Ophthalmic Solution	0.5%	➤ Subscribe	2012-10-19
➤ Subscribe	Gel	0.04%	➤ Subscribe	2010-12-20
➤ Subscribe	Ophthalmic Solution	1.5%	➤ Subscribe	2013-09-09
➤ Subscribe	Gel	1.2%/0.025%	➤ Subscribe	2010-12-17
➤ Subscribe	Gel	0.77%	➤ Subscribe	2006-05-10
➤ Subscribe	Lotion	0.1%	➤ Subscribe	2016-08-31
➤ Subscribe	Extended-release Tablets	174 mg	➤ Subscribe	2009-09-28
➤ Subscribe	Cream	3.75%	➤ Subscribe	2012-08-08
➤ Subscribe	Extended-release Tablets	522 mg	➤ Subscribe	2009-12-24
➤ Subscribe	For Inhalation Solution	6 gm/vial	➤ Subscribe	2014-05-22
➤ Subscribe	Extended-release Tablets	420 mg	➤ Subscribe	2005-04-25
➤ Subscribe	Rectal Gel	5 mg/mL, 4mL pre-filled syringe	➤ Subscribe	2008-12-08
➤ Subscribe	Extended-release Tablet	55 mg and 80 mg	➤ Subscribe	2010-12-02
➤ Subscribe	Gel	1.2%/2.5%	➤ Subscribe	2012-12-20
➤ Subscribe	Extended-release Tablets	150 mg and 300 mg	➤ Subscribe	2004-09-21
➤ Subscribe	Gel	0.1%	➤ Subscribe	2010-07-08
➤ Subscribe	Ophthalmic Solution	0.07%	➤ Subscribe	2013-07-26
➤ Subscribe	Capsules	75 mg	➤ Subscribe	2011-06-06

International Patents for BAUSCH Drugs

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
Poland	2234621	⤷ Subscribe
South Korea	20180101640	⤷ Subscribe
Mexico	2010007230	⤷ Subscribe
European Patent Office	3715345	⤷ Subscribe
Singapore	11201509051V	⤷ Subscribe
South Korea	20230019228	⤷ Subscribe
South Korea	101817928	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for BAUSCH Drugs

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1948158	1690020-1	Sweden	⤷ Subscribe	PRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
0480717	SPC/GB98/025	United Kingdom	⤷ Subscribe	PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115
2826776	122021000025	Germany	⤷ Subscribe	PRODUCT NAME: EINE KOMBINATION VON (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANCARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND (B) N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1306 20181031
1304992	SPC/GB13/061	United Kingdom	⤷ Subscribe	PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
0656775	28/2000	Austria	⤷ Subscribe	PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
2563920	CR 2019 00001	Denmark	⤷ Subscribe	PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710
0656775	CR 2000 00018	Denmark	⤷ Subscribe	PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for BAUSCH

Paragraph IV (Patent) Challenges for BAUSCH drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing